In Vivo Analyses of Transcriptional Coactivator Domains

转录辅激活因子结构域的体内分析

• 批准号: 7036438
• 负责人: PAUL K BRINDLE
• 金额: $ 7.5万
• 依托单位: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-07-01 至 2006-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7036438
• 关键词: binding proteins; cAMP response element binding protein; developmental genetics; genetically modified animals; hypoxia inducible factor 1; immunoprecipitation; laboratory mouse; microarray technology; oligonucleotides; oncoproteins; point mutation; protein structure function; transcription factor

CREB-binding protein (CBP, CREBBP) and the closely related E1A-binding protein p300 (EP300) are transcriptional coactivators that interact physically or functionally with about 10 percent of the estimated 2,000 mammalian transcriptional regulatory proteins. Both genes are required for normal development and physiology, and altered-function- and inactivating-mutations occur in cancer, indicating that CBP and p300 can function both as oncoproteins and as tumor suppressors. Several major unresolved questions remain with regard to the biological and transcriptional roles of CBP and p300. First, it is largely unknown what roles the multiple different transcription factor-binding domains of CBP and p300 play in development and tumorigenesis in vivo. Second, many in vitro studies indicate that CBP and p300 are biochemically indistinguishable, but it is uncertain how redundant their functions are in vivo. Third, numerous in vitro transcription studies have shown that CBP and p300 are crucial coactivators, yet little is known regarding their roles in endogenous gene expression. Fourth, it is uncertain if different classes of coactivators function redundantly. These questions form the core of the application's broad, long-term, objectives, aspects of which will be approached by testing the in vivo functions of two specific protein-binding domains common to CBP and p300. Four strains of knock-in mutant mice have been generated. Two have point mutations on the surface of the KIX domain of CBP and p300 that inhibits the binding of the cAMP-responsive factor CREB and the hematopoietic factor c-Myb, and two strains that have a deletion mutation in the CH1 domain of CBP and p300 that abrogates the binding of the hypoxia-responsive factor HIF-1. Three specific aims will be pursued using these mice. Aim 1 is to elucidate the roles of the KIX domain of CBP and p300 in vivo. Aim 2 is to determine the roles of the CH1 domain of CBP and p300 in vivo. Aim 3 is to establish if CBP and p300 are biochemically redundant in vivo.

creb结合蛋白（CBP， CREBBP）和密切相关的e1a结合蛋白p300 （EP300）是转录共激活因子，与估计的2000种哺乳动物转录调节蛋白中的约10%发生物理或功能相互作用。这两个基因都是正常发育和生理所必需的，而功能改变和失活突变发生在癌症中，这表明CBP和p300既可以作为癌蛋白，也可以作为肿瘤抑制因子。关于CBP和p300的生物学和转录作用，仍有几个主要的未解决的问题。首先，CBP和p300的多个不同转录因子结合域在发育和发育过程中发挥的作用在很大程度上是未知的